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1684-1182/Copyright ª 2014, Taiwan S
BY-NC-ND license (http://creativecomBackground: Respiratory syncytial virus (RSV) infection is an important cause of viral respira-
tory tract infection in children. This retrospective study describes the clinical characteristics
of severe RSV infection and determines the risk factors for death.
Methods: Patients were identified through a review of all patients discharged with a diagnosis
of RSV lower respiratory tract infection and admitted to hospital in the pediatric intensive care
unit (PICU) of a tertiary medical center between July 1, 2001 and June 30, 2010. The medical
and demographic variables were recorded and analyzed.
Results: The 186 RSV-positive patients admitted to the PICU had a median age of 5.3 months
(interquartile range 2.3e12.4 months) and included 129 boys and 57 girls. Among them, 134
had at least one underlying disease: prematurity in 92, neurological disease in 57, bronchopul-
monary dysplasia in 40, congenital heart disease in 26, hematological malignancies in 11, and
Down’s syndrome in nine patients. The 10 patients who died from RSV-related causes had a me-
dian age of 20.8 months (interquartile range 6.6e89.2 months) and all had a comorbidity. In
multivariate analysis, the risk factors for death in severe RSV infection were Down’s syndrome
(odds ratio 7.20, 95% confidence interval 1.13e45.76; pZ 0.036) and nosocomial RSV infection
(odds ratio 4.46, 95% confidence interval 1.09e18.27; p Z 0.038).
Conclusion: Down’s syndrome and nosocomial RSV infection are significantly associated with
death in severe RSV infections. Clinicians should be alert to these conditions.of Pediatrics, Mackay Memorial Hospital, 92, Section 2, Zhongshan North Road, Taipei 10449, Taiwan.
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Respiratory syncytial virus (RSV) is an important cause of
acute lower respiratory tract infection (LRTI) in children
younger than 5 years of age. In 2005, RSV was estimated to
be responsible for at least 3.4 million episodes of severe
LRTI requiring admission to hospital in children worldwide
and caused 66,000e199,000 deaths in children younger
than 5 years old.1 In Switzerland, RSV infections cause
intermediate or intensive care unit (ICU) admissions of
approximately 1e2% of each annual birth cohort.2 In a
retrospective study in Hong Kong, the rate of RSV-
associated ICU admissions was 2.4% among 4912 RSV-
positive pediatric patients.3
Many studies have shown that patients at high risk of
severe RSV disease include premature infants,4,5 children
with hemodynamically significant congenital heart disease
(CHD),4,6,7 patients with bronchopulmonary dysplasia
(BPD),4,5,8 and those who are immunocompromised.6,9e11
However, data regarding risk factors for death in severe
RSV infection remain limited. The aim of this retrospective
study was to identify the clinical characteristics of patients
admitted to the pediatric intensive care unit (PICU) with
RSV infection and the risk factors for death.
Materials and methods
Ethics statement
The Ethics Committee of Mackay Memorial Hospital, Taipei,
Taiwan approved this study (Institute Review Board number
MMH-I-S- 627, protocol title “Clinical Features of Pediatric
Respiratory Syncytial Virus Infections: Risk Factors and
Outcome”).
Patient inclusion
Patients were identified through a review of medical re-
cords from July 1, 2001 to June 30, 2010. This study used
data from a 12-bed PICU in a tertiary medical center.
Patients aged 18 years and discharged with a diagnosis
of RSV LRTI were evaluated. The diagnosis was confirmed
by an RSV antigen immunofluorescence test and/or culture
from specimens taken from nasopharyngeal or throat
swabs. Patients who were admitted to the PICU and were
labeled as “severe” were enrolled into this study.
The general policy was that patients who required me-
chanical respiratory support or intensive care were trans-
ferred to the PICU. In the PICU, respiratory support
included mechanical ventilation (conventional and high
frequency), nasal intermittent positive pressure ventila-
tion, nasal continuous positive airway pressure, and sup-
plemental oxygen only.Virology sampling and investigations
Diagnostic samples, including nasopharyngeal aspirates for
the RSV antigen test and throat virus cultures, were ob-
tained by residents, nurses, or PICU staff members. The RSV
was identified using IMAGEN Respiratory Syncytial Virus
(Oxoid Ely Ltd, Hampshire, UK), a qualitative immunofluo-
rescence test for the direct detection of RSV in clinical
specimens. Throat swabs for viral culture used standard cell
culture methods.
Treatment with ribavirin
Ribavirin treatment was used for PICU patients younger
than 6 years of age who had RSV LRTI and least one of the
following: (1) high-risk for RSV infection, including immu-
nocompromised patients, prematurity, or patients with
CHD, BPD, or a malignancy being treated with chemo-
therapy; (2) severe respiratory distress (PaO2  65 mmHg or
SaO2  90%); and (3) requiring ventilator support. Ribavirin
(20 mg/mL) was given via continuous aerosol administration
for 12e18 hours daily for 3 days. However, ribavirin became
unavailable in Taiwan from February 2009.
Definitions of variables
Children with gestational age <37 weeks were regarded as
preterm. Hemato-oncological diseases included acute lym-
phocytic leukemia, acute myeloid leukemia, chronic
myeloid leukemia, and lymphoma. Congenital hemodynam-
ically significant heart diseases or cyanotic heart diseases
were defined as CHD. Patients with atrial septal defect were
excluded from the study. Neurological diseases included
cerebral palsy, neuromuscular diseases, or other central
nervous system abnormalities. Patients with seizures were
excluded from this category. Nosocomial RSV infection was
defined as symptoms or signs of RSV infection developing 72
hours or more after admission for other diagnoses.
Statistical analysis
Frequency distribution analysis was used to describe the
patients’ baseline characteristics. Median and interquartile
ranges (IQRs) were used to interpret the demographic dis-
tributions. Continuous variables were expressed as a me-
dian with IQR and were compared using the Student t test
or the ManneWhitney U test. Categorical variables were
presented as frequencies and percentages and were
compared using the c2 or Fisher’s exact test as appropriate.
Univariate analysis was performed to evaluate the rela-
tionship between the variables and death. The factors were
also analyzed using a multivariate model built by backwards
elimination (a significance level of 5%) to assess the
Respiratory syncytial virus infection risk factors 739relationship to death. Statistical significance was set at
p < 0.05. All analyses were performed using SPSS version
17.0 software (IBM Corporation, Somers, NY, USA).
Results
Demographic data and clinical characteristics
A total of 5675 patients proved to have an RSV infection,
including 186 who were admitted to the PICU. Severe in-
fections accounted for 3.3% of RSV infections. Of the 186
patients, 129 were boys and 57 were girls (ratio 2.3:1).
Their mean age was 5.3 months (range 0.2e168.1 months).
Ninety-two (49.5%) patients were born prematurely, 46
(24.7%) patients had a nosocomial RSV infection, and 54
(29.0%) patients received treatment with ribavirin. One
hundred and thirty-four (72.0%) patients had at least one
underlying disease. Respiratory support included mechani-
cal ventilation (29.5%), nasal intermittent positive pressure
ventilation (30.1%), nasal continuous positive airway pres-
sure (10.8%), and oxygen supplement (29.5%). Ten patients
died giving a mortality rate of 5.4% (Table 1).
Characteristics of the patients who died
Table 2 lists the characteristics of the patients who died.
Patient 1 had a very long stay in hospital as a result of
complicated underlying diseases. This patient had a noso-
comial RSV infection and Serratia marcescens sepsis, which
caused his death. Patient 5 had a ventricular septal defect,Table 1 Characteristics of children admitted to the
pediatric intensive care unit for respiratory syncytial virus
infection





Median (IQR) age at diagnosis (mo) 5.3 (2.3e12.4)
Prematurity 92 (49.5)
Pre-existing disease 134 (72.0)
Bronchopulmonary dysplasia 40 (21.5)
Congenital heart disease 26 (14.0)
Down’s syndrome 9 (4.8)
Hemato-oncological disease 11 (5.9)
Neurological disease 57 (30.6)
None 52 (28.0)
Nosocomial acquisition 46 (24.7)
Treatment with ribavirin 54 (29.0)
Respiratory support
Oxygen supplement 55 (29.5)
NCPAP 20 (10.8)
NIPPV 56 (30.1)
Mechanical ventilation 55 (29.5)
Death 10 (5.4)
IQR Z interquartile range; NCPAP Z nasal continuous positive
airway pressure; NIPPV Z nasal intermittent positive pressure
ventilation.patent ductus arteriosus, and pulmonary hypertension. His
condition deteriorated and he died a few days after sur-
gery. His RSV infection was identified and was posited to
have aggravated the burden of pulmonary and cardiac dis-
ease in this patient.
Analysis of risk factors for death
In univariate analysis (Table 3), hemato-oncological dis-
eases [odds ratio (OR) 9.0, 95% confidence interval (CI)
1.95e41.45; p Z 0.015], nosocomial infections (OR 5.10,
95% CI 1.37e18.97; p Z 0.016), and treatment with riba-
virin (OR 6.40, 95% CI 1.59e25.79; p Z 0.007) were asso-
ciated with death. Among the continuous variables, death
was associated with a longer duration of fever and lower
platelet counts. The duration of fever among survivors was
4.8  8.3 days and among non-survivors was 8.8  4.7 days
(p Z 0.038). The platelet count among survivors was
364.4  171.5  103/mm3 and among non-survivors was
187.8  110.1  103/mm3 (p Z 0.001).
Using multiple logistic regression analysis (Table 4),
Down’s syndrome (OR 7.20, 95% CI 1.13e45.76; p Z 0.036)
and nosocomial RSV infection (OR 4.46, 95% CI 1.09e18.27;
p Z 0.038) were predictive factors for death. Older chil-
dren have more risk for death from RSV (OR 1.024, 95% CI
1.01e1.04; p Z 0.002).
Discussion
In this study, all the children who died from severe RSV
disease had pre-existing diseases. This study also showed
that Down’s syndrome and nosocomial RSV infection are
significant risk factor for death in severe RSV infection.
Previous studies have shown that Down’s syndrome is a
major risk factor for RSV LRTI. There are many possible
explanations. Children with Down’s syndrome have an
increased rate of comorbidities with both CHD and pulmo-
nary hypertension, which are two independent risk factors
for RSV LRTI.12,13 Patients with Down’s syndrome, even
without coexisting risk factors such as CHD, still have higher
risks of being admitted to hospital for RSV LRTI.14 Other
hypothesized mechanisms include hypotonia,15 more
injury-prone lungs,16 an abnormal upper respiratory anat-
omy,15 and altered lung growth.17 Immunological impair-
ment associated with Down’s syndrome is also a potential
mechanism, as demonstrated in many aspects including
defects in adaptive18,19 and intrinsic immunity,20,21 dimin-
ished numbers of B and T cells due to abnormal thymus
function,21 decreased lymphocyte numbers and responses
to stimulations,22 reduced phagocytosis by neutrophils,23
and lower serum immunoglobulin levels.24
Nosocomial RSV infection is also a risk factor for death in
severe RSV infection.25 Comorbidity may confound the
relationship between nosocomial RSV infection and death.
In previous studies, children with BPD, CHD, and impaired
immune systems had increased incidences of nosocomial
RSV infection.9,26e29 This may be due to the longer stay in
hospital and in the ICU and more exposure to potential
cross-infection.
In multivariate analysis, older children have a higher risk
for death from RSV infection. Older children often have
Table 2 Characteristics of the ten patients with severe respiratory syncytial virus infections who died




1 M 7.0 Prematurity, rickets, short bowel syndrome Yes No
2 M 5.2 Prematurity, BPD, Down’s syndrome No Yes
3 M 11.0 Prematurity, BPD Yes Yes
4 F 8.6 Prematurity, bronchopulmonary dysplasia No Yes
5 M 54.4 VSD, PDA, pulmonary hypertension No No
6 M 86.3 ALL Yes Yes
7 F 30.5 Cerebral palsy No No
8 F 5.6 Down’s syndrome, VSD Yes Yes
9 M 168.1 ALL Yes Yes
10 M 97.6 ALL Yes Yes
ALL Z acute lymphoblastic leukemia; BPD Z bronchopulmonary dysplasia; F Z female; M Z male; PDA Z patent ductus arteriosus;
VSD Z ventricular septal defect.
740 Y.-I. Lee et al.milder symptoms than younger children when they have an
RSV infection. However, in older children with severe RSV
infection, death may be related to their underlying condi-
tions and they may therefore present with more severe
infections and more complications.
In this study, only 12 virus isolates underwent serotyp-
ing. Nine were RSV-A and three were RSV-B. A previous
study has shown that there is no difference in severity of
disease caused by RSV-A or RSV-B.30 However, the sample
size in this study was too small to include this variable in
the analysis.
Ribavirin is a guanosine analogue with antiviral activity
against a variety of viruses. In 1985, the United States Food
and Drug Administration approved its aerosol form for use
in infants and children with RSV bronchiolitis.31 Some pre-
vious studies have shown that treatment with ribavirin can
reduce the severity of illness, the duration of mechanical
ventilation, the length of hospital stay, and viral sheddingTable 3 Univariate analysis of the risk factors and death in pa
Variable Survival (n Z 176)
Male sex 122 (69.3)
Age (mo) 12.1  21.9
Preterm birth 88 (50.0)
Bronchopulmonary dysplasia 37 (21.0)
Congenital heart disease 24 (13.6)
Down’s syndrome 7 (4.0)
Neurological disease 56 (31.8)
Hemato-oncological disease 8 (4.5)
Nosocomial RSV infection 40 (22.7)
Treatment with ribavirin 47 (26.7)
Duration of fever (d) 4.8  8.3
Duration of hospitalization (d) 37.6  51.0
Duration of PICU stay (d) 9.5  11.8
Hemoglobin (g/dL) 12.2  10.7
White blood cell count (103/mm3) 13.0  8.8
Platelet (103/mm3) 364.4  171.5
C reactive protein (mg/dL) 3.1  5.9
Data are presented as n (%) or mean  SD.
CI Z confidence interval; OR Z odds ratio; PICU Z pediatric intensiin RSV bronchiolitis.32e34 However, other studies have not
shown these benefits.35e37 A 2004 systematic review of
randomized trials showed that trials of treatment with
nebulized ribavirin lacked sufficient power to provide reli-
able estimates of the effects.31 The American Academy of
Pediatrics no longer recommends the routine use of riba-
virin because of the high costs, concerns for its teratogenic
potential in pregnant health care staff, and uncertainty
about its effectiveness. Nonetheless, ribavirin may still be
considered for selected patients with potentially life-
threatening RSV infection. In this study, ribavirin was only
given to a few patients. As ribavirin has not been available
in Taiwan since February 2009, the effects of treatment
with ribavirin are difficult to evaluate in this study.
Palivizumab is a monoclonal antibody produced by re-
combinant DNA technology used in the prevention of RSV
infections. It has been universally used in Taiwan since
December 2010 for specific high-risk patients, includingtients with respiratory syncytial virus infection
Death (n Z 10) OR (95% CI) p
7 (70.0) 1.03 (0.26e4.15) > 0.99
47.4  54.7 0.072
4 (40.0) 0.67 (0.18e2.44) 0.747
3 (30.0) 1.61 (0.40e6.53) 0.450
2 (20.0) 1.58 (0.32e7.91) 0.633
2 (20.0) 6.04 (1.08e33.84) 0.077
1 (10.0) 0.24 (0.03e1.93) 0.288
3 (30.0) 9.00 (1.95e41.45) 0.015
6 (60.0) 5.10 (1.37e18.97) 0.016
7 (70.0) 6.40 (1.59e25.79) 0.007
8.8  4.7 0.038
80.6  116.3 0.274
14.4  15.6 0.374
15.6  15.2 0.534
11.2  8.7 0.552
187.8  110.1 0.001
8.32  9.5 0.140
ve care unit; RSV Z respiratory syncytial virus.
Table 4 Multivariate analysis of the variables associated
with death from respiratory syncytial virus infection
Variable OR (95% CI) p
Age 1.02 (1.01e1.04) 0.002
Down’s syndrome 7.20 (1.13e45.76) 0.036
Nosocomial RSV infection 4.46 (1.09e18.27) 0.038
CI Z confidence interval; OR Z odds ratio; RSV Z respiratory
syncytial virus.
Respiratory syncytial virus infection risk factors 741those with prematurity with gestational age 28 weeks,
prematurity with gestational age 35 weeks and BPD, and
patients with hemodynamically significant heart disease.
The patients in this study were recruited before pal-
ivizumab was used.
RSV is primarily spread by close contact with aerosols of
infectious respiratory secretions and medical staff are
often instrumental in its transmission. RSV is a labile virus
and is rapidly inactivated by alcohol, dishwashing de-
tergents, and antibacterial hand soaps. Thus hand-washing
probably plays the most important part in infection control.
Although there are various barrier methods, the isolation of
RSV-positive patients in single rooms is recommended.38
This study is limited by its retrospective nature and
small sample size. Further research is warranted to deter-
mine other risks factors for death in RSV infection.
In children with severe RSV disease, nosocomial RSV
infection is associated with increased risk of death. Pre-
existing diseases and co-morbidities, particularly Down’s
syndrome, are significant risk factors for death from severe
RSV infection.
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